Gestational Trophoblastic Disease: Diagnosis Questions

This page is for anyone recently told they may have gestational trophoblastic disease. It explains the main types, how extent and risk are described, and questions to ask your care team.

Gestational trophoblastic disease, or GTD, is not one single condition. It is a group of conditions. The exact type changes what happens next. NCI lists a physical and pelvic exam, a pelvic ultrasound, and blood tests for beta-hCG. That is a hormone your body makes during pregnancy. Ask which test confirmed your exact type.

Ask the clinician to write the complete diagnosis, including subtype, stage, or risk group when those terms apply. Then ask which result established it.

GTD falls into two broad groups. Knowing which one you have changes the entire conversation.

Hydatidiform moles are slow-growing tumors that are usually not cancer. They can be complete, meaning the tissue has no genetic material from the mother. Or they can be partial, meaning it has extra genetic material from the father. Most moles stay benign. Some types become cancer.

Gestational trophoblastic neoplasia, or GTN, is almost always cancer. It includes invasive moles, which grow into the muscle wall of the uterus. It includes choriocarcinoma, which can spread into blood vessels and distant organs. It also includes two much rarer types: placental-site trophoblastic tumor and epithelioid trophoblastic tumor.

• Is this a hydatidiform mole, or is it gestational trophoblastic neoplasia?
• If it is a mole, is it complete or partial?
• If it is GTN, which specific type: invasive mole, choriocarcinoma, or one of the rarer forms?
• Are stains, chromosome tests, or other specialized results still pending?
• Would review by a pathologist who regularly sees this condition be useful, given how rare it is?

Ask whether your type is staged. GTN is staged. It uses a four-stage system based on where the disease has reached: confined to the uterus, spread to nearby structures, reached the lungs, or reached other distant organs.

For invasive moles and choriocarcinoma, doctors also sort cases into low-risk or high-risk groups. That grouping weighs:

• your age
• the type of pregnancy before it
• your beta-hCG level
• the size of the tumor
• whether it has spread

This risk group, not just the stage, often decides how intensive treatment needs to be.

Ask what the team knows about the extent of disease and what remains uncertain. A stage or risk group should be explained in words, not only as a number.

Beta-hCG is a key marker for finding GTD. Ask how it is used to track your care afterward. Ask how often your beta-hCG will be checked, both during and after treatment. Ask what it would mean if the level stopped falling as expected.

Ask where the pathology slides, ultrasound images, and beta-hCG results are stored, and how to request them. Ask whether the current center can send them directly to another center. A second opinion does not require rejecting the first team. GTD is rare, so a second opinion can confirm the plan, or catch a detail worth discussing. That matters, because the exact subtype changes treatment so much.

GTD grows from tissue that would normally form the placenta during pregnancy. That can make the diagnosis feel tangled up with pregnancy loss, even though it is being treated as a medical condition in its own right. It is fair to ask your team directly how this diagnosis relates to any pregnancy you were expecting, and what it means, if anything, for future pregnancies. These are reasonable questions, not a distraction from the medical plan.

Before the visit ends, write down the next test, appointment, responsible person, and expected timing. Ask how results will arrive, and who will explain them if they show up in a portal first.

The most useful outcome is a short sentence: "This is what we know, this is what we are waiting for, and this is the decision that comes next."

• National Cancer Institute — Gestational Trophoblastic Disease Treatment (PDQ).